RGD-modified endostatin fragments showed an antitumor effect through antiangiogenesis

Anti-cancer Drugs
Chunyan PuYongbing Li

Abstract

EDSM, an endostatin-derived synthetic polypeptide, contains the amino acids 6-48 of endostatin from its N-terminus, which could inhibit human umbilical vein endothelial cell (HUVEC) migration and tumor growth. To increase the targeted delivery of EDSM to tumors and further enhance its antiangiogenic activity, the RGD sequence (Arg-Gly-Asp) was introduced into EDSM and two peptides were obtained: EDSM-X with RGD on the N-terminus of EDSM and EDSM-Y with RGD on the C-terminus. Both modified peptides showed a significant antiangiogenic activity in the HUVEC migration assay, the HUVEC tube formation assay, and the murine aortic ring formation assay in vitro. In agreement with the in-vitro data, EDSM-X and EDSM-Y also showed a significant antitumor activity in vivo. From the cell adhesion assay, it was confirmed that the molecular target of the modified peptides on HUVECs was integrin αvβ3, rather than integrin α5β1. Furthermore, EDSM-Y exhibited more potent antiangiogenic activity and antitumor activity than EDSM-X in vitro and in vivo, and this phenomenon was attributed to the difference in the two modified peptides in their three-dimensional structure modeling and their molecular dockings with integrin αvβ3.

References

Nov 18, 1971·The New England Journal of Medicine·J Folkman
Aug 12, 1971·The New England Journal of Medicine·J Folkman
May 18, 1999·Biochemical and Biophysical Research Communications·M DhanabalV P Sukhatme
Feb 7, 2001·Proceedings of the National Academy of Sciences of the United States of America·M RehnK Vuori
Feb 13, 2001·Current Opinion in Genetics & Development·R K Assoian, M A Schwartz
Feb 13, 2003·Experimental Cell Research·Maria Grazia CattaneoLucia Maria Vicentini
Apr 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Akulapalli SudhakarRaghu Kalluri
Feb 20, 2004·The Journal of Biological Chemistry·Sara A WickströmJorma Keski-Oja
Feb 27, 2004·Nature·Judah Folkman, Raghu Kalluri
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jan 18, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Amitava MitraBruce R Line
May 4, 2005·Protein Expression and Purification·Han-Mei XuZi-Chun Hua
Sep 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Torsten KesslerRolf M Mesters
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerBrian I Rini
Dec 27, 2005·Experimental Cell Research·Judah Folkman
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaLeonard B Saltz
Mar 29, 2007·Journal of Cellular Biochemistry·Azza GramounMorris F Manolson
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Sep 20, 2008·Bioconjugate Chemistry·Han-Mei XuYing Wang
Dec 1, 2009·Biochemical and Biophysical Research Communications·Renhua SunWenbing Yao
Oct 5, 2010·Nature Reviews. Drug Discovery·Dermot CoxNiamh Moran
Jun 15, 2011·Bioconjugate Chemistry·Hanmei XuZhendong Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.